News Release - Eli Lilly and Company
WEBMay 13, 2022 · FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 …
Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
WEBAug 20, 2024 · A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight...
News Release - Eli Lilly and Company
WEBMay 14, 2024 · Lilly is deeply concerned that products fraudulently claimed by compounding pharmacies or counterfeiters to be FDA-approved tirzepatide, Mounjaro ®, or Zepbound ® may expose patients to serious health risks.
FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity ... - CNN
WEBNov 8, 2023 · The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes...
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
News Release - Eli Lilly and Company
WEBSep 19, 2023 · Because of this, Lilly filed lawsuits to protect patient safety and stop the unlawful marketing and sale of non-FDA approved compounded products fraudulently claiming to be Mounjaro® (tirzepatide) by medical spas, wellness centers and compounding pharmacies.
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better …
WEBAug 8, 2024 · INDIANAPOLIS (AP) — Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit ...
WEBApr 30, 2024 · Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
Eli Lilly diabetes drug Mounjaro supply improves in U.S.
WEBNov 2, 2023 · Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread shortages. However, the pharmaceutical giant noted that it is...
Lilly exec eyes more weight-loss drug launches this year
WEBJan 16, 2024 · Eli Lilly on Tuesday said it plans to launch its weight-loss drug Mounjaro in new countries this year as it expands manufacturing capacity.